Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
2
TLD-1433 Exhibits Early Efficacy in BCG-Unresponsive NMIBC CIS
3
FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC
4
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
5